Additional file 1 of Lipidomics profiling reveals distinct patterns of plasma sphingolipid alterations in Alzheimer’s disease and vascular dementia

Additional file 1: Supplementary Table S1. Diagnostic criteria of clinical subgroups for this study. Supplementary Table S2. Summary of Neuropsychological Battery and Component Tests. Supplementary Table S3. List of quantifiable lipid species in this study. Supplementary Table S4. Median concentrations of SPs in absence or presence of comorbidity or ApoE4 allele. Supplementary Table S5. SPs fold change and BH-p values in presence versus absence of comorbidity or ApoE4 allele. Supplementary Table S6. Median concentrations (nM) of SPs in NCI, CIND, AD and VaD. Supplementary Table S7. SPs Fold change and BH-p values in CIND, AD, VaD compared to NCI. Supplementary Table S8. Associations of SPs and risk of AD or VaD diagnoses, expressed as odds ratio (OR) and BH-adjusted p-values. Supplementary Table S9. AUC values for individual SPs and selected multimarker panel for AD. Supplementary Table S10. AUC values for individual SPs and selected multimarker panel for VaD. Supplementary Table S11. Variables selected by stepwise backwards regression for AD. Supplementary Table S12. Variables selected by stepwise backwards regression for VaD.

附加文件1：补充表S1。本研究临床亚组诊断标准。
补充表S2：神经心理学成套测验及其分量表汇总。
补充表S3：本研究中可量化脂质物种清单。
补充表S4：存在共病或载脂蛋白E4（Apolipoprotein E4, ApoE4）等位基因与不存在上述情况时，SPs的中位浓度。
补充表S5：存在共病或载脂蛋白E4（Apolipoprotein E4, ApoE4）等位基因相较于不存在上述情况时，SPs的倍数变化及BH校正P值。
补充表S6：NCI、CIND、AD及VaD群体中SPs的中位浓度（单位：纳摩尔，nM）。
补充表S7：以NCI为参照，CIND、AD及VaD群体中SPs的倍数变化及BH校正P值。
补充表S8：SPs与AD或VaD诊断风险的关联情况，以优势比（Odds Ratio, OR）及BH校正P值表示。
补充表S9：单个SPs及筛选得到的多标志物组合用于AD诊断的受试者工作特征曲线下面积（Area Under the Curve, AUC）值。
补充表S10：单个SPs及筛选得到的多标志物组合用于VaD诊断的受试者工作特征曲线下面积（AUC）值。
补充表S11：针对AD通过逐步后退回归法筛选得到的变量。
补充表S12：针对VaD通过逐步后退回归法筛选得到的变量。